Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
about
New and emerging treatments for symptomatic tardive dyskinesiaRandomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Treatment of generalized dystonia.Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Liquid chromatography-tandem mass spectrometric assay for the determination of tetrabenazine and its active metabolites in human plasma: a pharmacokinetic study.The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.Disease Modifying Potential of Glatiramer Acetate in Huntington's DiseaseEffect of tetrabenazine on computerized dynamic posturography in Huntington disease patients.DNA methylation in Huntington's disease: Implications for transgenerational effectsEffort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effectsPromise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective.Brain networks in Huntington disease.Management of Huntington's disease: role of tetrabenazine.The vesicular monoamine transporter 2: an underexplored pharmacological target.Investigational drugs for the management of Huntington's disease: are we there yet?Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.Identification and management of tardive dyskinesia: A case series and literature review.Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.Pharmacological treatment of tardive dyskinesia: recent developments.The clinical challenges of akathisia.Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.Transforming Growth Factor-Beta Signaling in the Neural Stem Cell Niche: A Therapeutic Target for Huntington's Disease.Analysis of CYP2D6 genotype and response to tetrabenazine.Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.Selection of sucrose concentration depends on the effort required to obtain it: studies using tetrabenazine, D1, D2, and D3 receptor antagonists.The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.Dopamine, Effort-Based Choice, and Behavioral Economics: Basic and Translational Research.Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.Caffeine Modulates Food Intake Depending on the Context That Gives Access to Food: Comparison With Dopamine Depletion
P2860
Q24599912-E56D2016-B8BE-4295-A5CC-4E62BE49C096Q33714619-33CBED6D-2817-4B8A-BA67-167DCD2782A1Q34174964-B0B24A00-5376-4142-B6FB-EA031C0B0CDFQ34547558-8D2720C8-AAD9-4D37-A220-B88C7877AFFEQ34556884-53599F56-9BAA-491B-8487-18AA75805550Q35189617-E184AA05-39B4-45FF-9368-0BD622E494FFQ35782283-B0FE3977-9322-49B4-9DF1-7CA8CFB498F8Q36179540-61E4C181-D148-4690-84F4-B7E86F78DBD9Q36892975-0056B181-C981-4E62-960F-58DFF3447725Q37362447-7AFCB10F-422D-41D1-90C7-2BB90282D259Q37416376-4DFCEB31-4CFB-4732-A321-4B0AB95963FBQ37506497-E01A9DB1-36C4-473D-95CE-D7C4DEC31B71Q37834193-2AAD89B1-C0B5-4C09-9BE0-E55312371D3EQ37863463-5C7C49AE-2877-4F4B-BF01-2D7213AD0600Q38176494-056E9357-D08C-4FF5-A358-815769DE1991Q38236052-29241BF3-AAED-43B0-9E7A-333BBFC43B49Q38306593-1356901D-6406-489F-86C9-748F2FFAFAB4Q38545655-FC19C7AF-68C4-4303-A090-8E636240B4D2Q38555637-7970F484-5E3C-45C2-92C1-83D469D89018Q38657158-6EBB5A3D-F883-4E49-A657-DCAECE555B3DQ38670290-2C0AB328-6011-4EDF-9C32-1E81042CF827Q38673544-8DF2FD21-032A-4420-8869-2FE8676935F3Q38819771-DEA705F2-1BB6-4986-BA01-478F299D1E93Q38836831-D2A26605-4CF9-4504-A339-EE657760985CQ41249072-EC77F96E-77DF-4305-941B-8EC55743B05EQ41821958-AA9F2685-F4BB-420B-A367-8E962518FEB3Q43478633-8FBF8E58-70B9-4086-BE7B-604449A136EAQ47586487-9DE53262-5D60-4190-A728-654528CA80F1Q47680336-CB74733A-260E-4F20-8288-CFCBE41E873EQ48190081-0D966229-2D48-4A6C-8E11-CE17A3D9EC83Q52599712-7B299470-7F17-44E4-9C46-8C707F3565AFQ55132660-BE4D5E75-B8D0-4EAB-816D-8570430E65C8Q58761397-62F8F85B-AB98-403A-B6AB-3CD42DC87A44
P2860
Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@ast
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@en
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@nl
type
label
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@ast
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@en
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@nl
prefLabel
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@ast
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@en
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@nl
P1476
Tetrabenazine, a monoamine-dep ...... perkinetic movement disorders.
@en
P2093
David R P Guay
P304
P356
10.1016/J.AMJOPHARM.2010.08.006
P577
2010-08-01T00:00:00Z